Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals trades at 9.61% short interest—notably elevated for a pharma name—yet sits only 59.1 on the RSI, suggesting room before genuine overbought territory. The lack of a P/E ratio signals either negative earnings or transition dynamics, making valuation assessment murky despite the $12.0B market cap. The short concentration, combined with neutral momentum, hints at latent squeeze potential if catalysts emerge, though the absence of profitability metrics raises questions about near-term earnings visibility and the durability of any upside momentum.